Jan 19, 2024
January 26, 2025
This week’s newsletter included:
- Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
- First Patient Enrolled in Merit Medical’s MOTION Study
- bioMérieux Acquires LUMED
- Proposal to Restore R&D Expensing
- ACTION ALERT: Act Now to Restore Immediate R&D Expensing
- Medical Device Track from the 2023 Utah Life Sciences Summit
- Renalytix Update on kidneyIntelX.dkd LCD Consideration
- Utah Life Sciences Innovation Caucus Breakfast
- Life Sciences Day on Capitol Hill
Featured New Member Deal: Chubb
Recent News
- bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
- DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
- 2025 BIO International Recap
- Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
- Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services
- RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS
